Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation
Executive Summary
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.
You may also be interested in...
EU Nitrosamines Oversight Group Sets Priorities
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.
EU Nitrosamines Oversight Group Identifies Priority Topics
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a newly-created regulatory oversight group has identified several topics requiring further scientific discussion.
EU Regulators Take A Practical Approach To Addressing Nitrosamine Contamination
Regulators in the EU have decided on specific arrangements they plan to employ if sponsors detect and report nitrosamine impurities in their products being sold on the market.